Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.

Drug development research - 1 Sept 2020

Maffioletti Elisabetta, Valsecchi Paolo, Minelli Alessandra, Magri Chiara, Bonvicini Cristian, Barlati Stefano, Sacchetti Emilio, Vita Antonio, Gennarelli Massimo

Abstract excerpt

Antipsychotic drugs are the preferred choice for schizophrenia treatment; however, response is highly variable. In the context of the search for predictors of antipsychotic treatment effectiveness, the evaluation of response within 2 weeks has been indicated to predict long-term outcome. Moreover, a focus on symptomatological domains could be helpful to better characterize antipsychotic response, identifying more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Olanzapine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Receptor, Serotonin, 5-HT2A

Share to Risperidone

Share to Schizophrenia

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 32462699
DOI: 10.1002/ddr.21686

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.PMID 32462699Read ↗

The —1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patientsSemantic proximity Read ↗

The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.Semantic proximity Read ↗

The HTR2A rs6311 and rs6313 polymorphisms and atypical antipsychotics response in schizophrenia: a scoping review.Semantic proximity Read ↗

Association between the rs6313 polymorphism in the 5-HTR2A gene and the efficacy of antipsychotic drugs.Semantic proximity Read ↗

Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients.Semantic proximity Read ↗

Association evaluation of 5-HTR2A manifested salient contribution of rs6311 and rs6313 in increasing the occurrence of schizophreniaSemantic proximity Read ↗

Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia.Semantic proximity Read ↗

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic settingSemantic proximity Read ↗

Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients.Semantic proximity Read ↗

COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.Semantic proximity Read ↗

Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients.Semantic proximity Read ↗

The contribution of the 5-hydroxytryptamine receptor 2 A gene polymorphisms rs6311 and rs6313 to Schizophrenia in Iran.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.